A Study of Two Formulations of Ixekizumab in Healthy Participants: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for A Study of Two Formulations of Ixekizumab in Healthy Participants (NCT04259346), a randomized phase 1 study. The primary outcome is Pharmacokinetics (PK): Maximum Concentration (Cmax) of Ixekizumab.

2. Clinical Question

The trial’s stated purpose was to compare how much of each formulation gets into the bloodstream. Its primary outcome was pharmacokinetic rather than a measure of clinical benefit: it concerns the concentration of ixekizumab following administration. The registry also says information about side effects would be collected.

The posted primary summaries report a geometric mean Cmax of 9.66 micrograms per milliliter for the reference formulation and 9.97 micrograms per milliliter for the test formulation. The corresponding geometric coefficients of variation are 33.0 and 35.0. Those summaries describe the reported pharmacokinetic results; they do not, by themselves, establish whether the formulations meet a formal bioequivalence criterion. The registry record does not report a confidence interval, a hypothesis-test result, or an acceptance range for that decision.

3. Trial Design

This was a Phase 1, randomized, single-masked, parallel-group study in healthy participants. The registry record identifies Eli Lilly and Company as sponsor and reports enrollment of 245. The study began on 2020-02-05, had primary completion on 2021-02-19, and is marked completed. The registry describes the study duration as up to about four months for each participant.

Participants were assigned to one of two ixekizumab formulations. Both were described as 80 mg given by subcutaneous injection through an autoinjector. The reference formulation was described as approved by the Food and Drug Administration, while the test formulation was described as not approved. In a parallel design, each participant is assigned to one study group rather than receiving both study formulations in sequence. The registry does not report the allocation ratio.

“Single” masking indicates that the record classifies the study as single-masked, but which participants or study personnel were masked is not reported in the registry record. The record also does not state how randomization was generated or concealed. These details matter when considering how assignment might have been implemented, but they cannot be inferred from the design labels alone.

The primary pharmacokinetic outcome was assessed using samples scheduled from predose through Day 85. The PK outcome summaries include 112.0 participants in the reference group and 110.0 in the test group. These are the group counts attached to the primary outcome, not a breakdown of all enrolled participants. The safety figures use different at-risk counts, which are described separately. The registry does not explain the differences between those analysis counts and overall enrollment.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: Only participants who had all PK samples collected up to Day 85 or participants who had one missing PK sample after Day 15 but with at least 3 data points and R squared adjusted (Rsq adj) greater than (\>) 0.7 to calculate half-life parameter included in the analysis.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Population: All randomized participants who received at least one dose of study drug.

6. Primary Endpoint

The registry lists the primary outcome as Pharmacokinetics (PK): Maximum Concentration (Cmax) of Ixekizumab, measured over Predose, Day 3, Day 5, Day 8, Day 11, Day 15, Day 22, Day 29, Day 43, Day 57, Day 71 and Day 85 Post Dose.

The primary endpoint is maximum concentration, or Cmax, of ixekizumab in blood, reported in micrograms per milliliter. In general, Cmax is the highest concentration measured in a series of pharmacokinetic samples after a dose. It is used to describe the peak concentration reached during the measured sampling period. It is not a direct measure of total drug exposure over time, and it does not measure a clinical response.

The registry lists samples at predose and on Day 3, Day 5, Day 8, Day 11, Day 15, Day 22, Day 29, Day 43, Day 57, Day 71 and Day 85 post dose. Sampling at multiple points permits the concentration profile to be observed over time and supports the identification of a maximum among the measured concentrations. The registry describes the endpoint as evaluated from these PK data; it does not give further detail about how the maximum was derived when observations were missing.

The outcome is summarized using a geometric mean and a geometric coefficient of variation. In general, geometric summaries are used for positive measurements whose distributions may be asymmetric; the geometric mean represents a central value on a multiplicative scale. The coefficient of variation describes relative spread. These are descriptive summaries, not evidence on their own that two formulations are equivalent. The registry record does not report an inferential method or a prespecified criterion for judging bioequivalence.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The posted primary result is a descriptive pharmacokinetic summary. The record names Cmax as the endpoint, specifies a geometric mean as the summary parameter, and identifies geometric coefficient of variation as the measure of dispersion. It does not describe a statistical model for comparing the two groups. The following explanations distinguish what those descriptive measures mean in general from what the registry reports for this study.

What does a geometric mean describe?

In general, a geometric mean is a central summary for positive measurements. It is calculated on a multiplicative rather than an additive scale, making it useful when values are asymmetric or when relative changes are more meaningful than absolute changes. This does not establish that a particular statistical model was used in the trial. The registry reports geometric means for each group but does not report a model-based estimate of the contrast between them.

The posted group means are 9.66 micrograms per milliliter for the reference formulation and 9.97 micrograms per milliliter for the test formulation. These are estimates of central Cmax in the participants included in the endpoint analysis. They are not individual participant measurements, and they do not say how much one participant’s concentration differed from another’s. The registry does not provide the underlying individual measurements.

What does the geometric coefficient of variation describe?

In general, a coefficient of variation describes variability relative to the scale of the measurements. A geometric coefficient of variation is used with geometric summaries and positive values. The posted geometric coefficients of variation are 33.0 for the reference formulation and 35.0 for the test formulation. They describe dispersion within the groups; they are not confidence limits around the geometric means and are not a direct measure of uncertainty in a comparison between groups.

Uncertainty in a group estimate or in a contrast is commonly conveyed with a confidence interval. In general, a confidence interval describes a range of estimates compatible with the data and the specified method, and its width indicates precision. The registry record does not report confidence intervals for the group means or a contrast. It therefore does not provide a direct measure of the precision of the difference or ratio between the formulations.

What would a formal bioequivalence analysis add?

In general, formal bioequivalence assessment evaluates a comparison using a prespecified statistical criterion, commonly involving an estimated relative contrast and its uncertainty. The criterion determines what range of differences is considered compatible with bioequivalence for the relevant measure. This general description is not a claim about the analysis used in this trial. The registry record does not report the criterion, the comparison estimate, its confidence interval, or a test result. The posted geometric means alone cannot substitute for those details.

The registry does not list any analyses for the posted results. Consequently, no inferential method can be attributed to the study based on this record. In particular, it is not possible to identify whether any comparison was adjusted, what assumptions were checked, or how the sponsor assessed the endpoint against a formal decision threshold. Those statistical-plan details are not reported in the registry record.

How should the planning illustration be read?

In general, a sample-size calculation estimates how many participants a future study might need under assumptions about the effect to detect, variability, significance level, allocation and statistical method. The registry’s planning illustration is described as based on the observed effect, using a two-sided significance level of 0.05, equal allocation and a normal approximation; it considers target effects expressed as fractions of the observed effect. The illustration is not the trial’s own design justification. The specific sample-size justification for this trial is not reported in the registry record.

Planning illustrations do not establish the probability that the completed study detected an effect. They are not observed power. Their output depends on assumptions about the effect and analysis, and should be understood as hypothetical planning information rather than a result about the participants in this trial. The record’s description also distinguishes time-to-event planning, which uses total events, from other planning outputs, which are expressed as participants per arm. No additional planning values or target fractions are described in the registry record.

What can be inferred from the reported group counts?

The primary PK summaries include 112.0 participants in the reference group and 110.0 in the test group. These counts identify the groups underlying the posted outcome summaries, but they do not explain why not all enrolled participants appear in those analysis groups. The registry record gives a PK inclusion rule, discussed with missing data, but does not provide a full accounting of all participant flow or reasons for exclusion. The safety counts are reported on a different basis and should not be substituted for the PK analysis counts.

10. Multiplicity, Missing Data and Analysis Populations

The registry identifies Cmax as the primary outcome and reports three outcome measures overall. It lists zero analyses and zero posted secondary outcomes. A multiplicity procedure, such as an adjustment for testing several outcomes, is not reported in the registry record. With no posted inferential results, it is also not possible to determine which analyses, if any, were included in a formal multiplicity plan.

The record gives a specific population rule for the PK analysis. It includes participants with all PK samples collected through Day 85. It also allows participants with one missing PK sample after Day 15, provided they had at least 3 data points and an adjusted R-squared greater than 0.7 for calculating the half-life parameter. This describes the stated eligibility for the analysis population; it does not explain how missing concentration values were imputed, if they were imputed, or how any other missing data were handled.

The registry does not report the number of participants excluded from the PK analysis, reasons for exclusions, or a detailed participant-flow account. It also does not report sensitivity analyses examining the impact of missing data or alternative analysis populations. These omissions limit assessment of how the inclusion rule affected the posted summaries. No assumptions about missingness or imputation should be inferred from the inclusion rule alone.

The safety results use at-risk counts of 126 for the reference formulation and 119 for the test formulation, rather than the PK outcome group counts. The record does not explain the distinction. These separate counts should be read within their respective outcome contexts, not treated as interchangeable analysis populations.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

Most frequent non-serious adverse event terms

The registry reports zero serious adverse events among 126 participants at risk in the reference group and zero among 119 at risk in the test group. It also reports zero deaths in each group. These are the posted counts for the safety categories, not estimates of event rates or comparisons between formulations. No serious adverse event terms are listed.

Counts should be interpreted with their reported at-risk denominators. A zero count means that no events in that category were recorded for the group in the registry results; it does not establish that an event is impossible or that the formulations have identical safety profiles. The registry record does not provide confidence intervals or a statistical comparison for these figures.

The record also lists other adverse events affecting 36 participants in the reference group and 14 in the test group. Those figures are separate from the serious adverse event counts. The registry does not provide additional detail about event types, severity, timing, or how the events were attributed. Safety figures from this study should therefore be read as reported observations within this trial, not as a complete characterization of safety.

12. What the Result Does, and Does Not, Mean

The registry results describe a randomized Phase 1 comparison of two ixekizumab formulations in healthy participants. For the primary pharmacokinetic endpoint, the reference group had a geometric mean Cmax of 9.66 micrograms per milliliter and the test group had a geometric mean of 9.97 micrograms per milliliter. The geometric coefficients of variation were 33.0 and 35.0. These summaries provide a descriptive account of peak blood concentration in the analyzed groups.

They do not, on their own, answer whether the formulations are bioequivalent. A formal conclusion requires an appropriate contrast, its uncertainty, and a decision criterion. The registry record does not report those items or a statistical test for the comparison. It would therefore be inappropriate to characterize the posted point estimates as proof of equivalence or as evidence that equivalence failed.

The endpoint concerns pharmacokinetics, not clinical benefit. Cmax describes peak concentration and does not stand in for every aspect of drug exposure, safety, or response. The study enrolled healthy participants, and the registry record does not report clinical outcomes in a patient population. No conclusion about treatment effects or clinical use follows from these PK summaries alone.

The reported safety counts show zero serious adverse events and zero deaths in each group, alongside other adverse events affecting 36 participants in the reference group and 14 in the test group. These are registry counts for the trial, not a general safety comparison. The record does not report uncertainty estimates or a test of group differences for safety.

In short, the posted data describe group-level Cmax summaries and adverse event counts. They do not provide the inferential information needed to judge the precision of a formulation contrast or to make a formal bioequivalence determination. The original statistical plan, sample-size justification and further analysis details are not reported in the registry record.

13. Why This Trial Matters Statistically

This trial illustrates why the purpose and scale of a clinical study matter when reading a result. It was a Phase 1 study in healthy participants designed to compare two formulations through pharmacokinetic measurements. Its primary outcome was Cmax, a measure of peak concentration, rather than a clinical endpoint. That makes the reported summaries relevant to how the formulations were compared in this study, but not a direct measure of clinical benefit.

It also shows the difference between descriptive summaries and an inferential conclusion. Geometric means and geometric coefficients of variation characterize the groups. A formal assessment of similarity would require a comparison estimate and its uncertainty interpreted against a prespecified criterion. The registry record reports none of those inferential elements, so the descriptive numbers cannot settle the bioequivalence question on their own.

The study also provides a practical example of analysis populations differing across outcomes. The PK summaries have group counts of 112.0 and 110.0, while the safety results use at-risk counts of 126 and 119. The registry gives a PK inclusion rule but does not reconcile these counts with enrollment. A careful reading keeps the outcome-specific populations distinct rather than assuming that every reported count represents the same participants or analysis.

Finally, planning calculations and trial results answer different questions. The registry describes sample-size illustrations based on the observed effect and specified planning assumptions. Those illustrations are hypothetical and do not indicate observed power or reveal the original design justification. Separating planning information, descriptive findings and formal inference helps prevent claims that go beyond what the registry reports.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The principal limitation for interpreting the primary result is that the registry record provides group-level geometric means and variability summaries without a reported contrast, confidence interval, p-value or bioequivalence criterion. The formal statistical analysis plan and the method used to evaluate the primary comparison are not reported in the registry record. The available summaries therefore do not establish the precision of the comparison or whether a formal standard was met.

The PK analysis population is defined by sample availability and a rule involving an adjusted R-squared threshold for calculating the half-life parameter. However, the record does not report a complete accounting of participant flow, reasons for missing samples, exclusions, imputation methods, or sensitivity analyses. The relation between the PK analysis counts and enrollment is not explained. Safety at-risk counts differ from the PK counts, and the record does not explain that distinction.

Some masking and allocation details are also absent: the identity of those masked, the randomization procedure, allocation concealment and allocation ratio are not reported in the registry record. The original sample-size justification, any interim analyses and a detailed statistical plan are likewise not reported. These omissions should not be filled by assumptions based on standard practice.

For safety, the registry lists serious adverse event and death counts, as well as counts for other adverse events, but does not provide detailed event descriptions or uncertainty estimates. The trial’s healthy-participant setting and pharmacokinetic endpoint also limit what can be concluded about clinical outcomes. These features frame interpretation of the registry results; they do not establish that any unreported analysis or event did or did not occur.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: A Study of Two Formulations of Ixekizumab in Healthy Participants — NCT04259346.
• Registry record last updated 2022-04-08; status last verified 2022-02-01.
• Results first posted 2022-04-08.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

The registry record identifies NCT04259346 as a completed, randomized, single-masked, parallel Phase 1 study sponsored by Eli Lilly and Company. It compared an 80 mg reference ixekizumab formulation with an 80 mg test formulation, both administered by subcutaneous injection via autoinjector, in healthy participants. Enrollment was 245. The study began on 2020-02-05, and primary completion was on 2021-02-19.

The primary outcome was maximum ixekizumab concentration in blood, summarized by geometric mean and geometric coefficient of variation over sampling through Day 85. The posted summaries were 9.66 micrograms per milliliter for the reference group and 9.97 for the test group. The registry does not report a formal comparison or bioequivalence decision. Safety results include zero serious adverse events and zero deaths in each group, with other adverse events also reported.